Well StudiedHealing & RecoveryLongevity

TB-500

Thymosin Beta-4 Fragment

Synthetic Fragment (17-23) of Thymosin Beta-4

Half-life

~2 hours

Chain length

43 amino acids (full-length profile)

Reference frequency

2-3x weekly (e.g., Monday, Wednesday, Friday)

Research overview

DoseGear research brief

A synthetic 7-amino acid fragment corresponding to the actin-binding region of thymosin beta-4, originally developed for equine use with retained tissue repair properties. TB-500 acts as principal actin-sequestering protein, regulating cell migration, promoting angiogenesis, reducing inflammation, and activating stem cell differentiation.

Mechanism of action

Acts as principal actin-sequestering protein, regulating cell migration, promoting angiogenesis, reducing inflammation, and activating stem cell differentiation for comprehensive regenerative effects.

Compound background

Development & research timeline

Study windows describe what researchers measured, not when an individual should expect a result.

Origin & development

Identified in the source as a synthetic thymosin-beta-4 actin-region fragment; naming varies across products.

What it is researched for

Proposed repair and cell-migration applications; fragment-specific evidence must be distinguished from full-length thymosin beta-4.

Research observation window

Not reported for the exact fragment product.

Reference data

Lyophilized vial injectable protocols

Not personalized dosing instructions

Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.

Research context	Amount	Frequency	Route
General tissue repair	2-3mg	2x weekly	SubQ or IM
Serious injury recovery	4-5mg	3x weekly	SubQ near injury site
Athletic enhancement	2-3mg	2x weekly	SubQ
Chronic conditions	3-4mg	2-3x weekly	SubQ or IM
Maintenance	2mg	1-2x weekly	SubQ
Post-surgical recovery	3-5mg	3x weekly	SubQ

Reference cycle

6-8 weeks for active healing

Reference storage

Reconstituted: 2-8°C, use within 28 days

Safety context

Reported side effects

Generally minimal side effects
Possible mild injection site reactions
Temporary fatigue in some users

Contraindications & cautions

Active cancer treatment (due to angiogenic effects)
Pregnancy or breastfeeding
Immunosuppressive medications (consult provider)
WADA prohibited for competitive athletes

Scientific references

01
The regenerative peptide thymosin beta-4 accelerates the rate of dermal healing in preclinical animal models and in patients
Scientific citationThe regenerative peptide thymosin beta-4 accelerates the rate of dermal healing in preclinical animal models and in patients. Annals of the New York Academy of Sciences (2012).
02
Development of thymosin beta4 for treatment of patients with ischemic heart disease
Scientific citationDevelopment of thymosin beta4 for treatment of patients with ischemic heart disease. Annals of the New York Academy of Sciences (2007).
03
Evaluation of skeletal and cardiac muscle function after chronic administration of thymosin beta-4 in the dystrophin deficient mouse
Scientific citationEvaluation of skeletal and cardiac muscle function after chronic administration of thymosin beta-4 in the dystrophin deficient mouse. PLoS One (2010).
04
Thymosin beta-4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial
Scientific citationThymosin beta-4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea (2015).

This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.

Related research profiles

Longevity